Founded in 2000, Galectin Therapeutics Inc. (GALT) is a biotechnology company based in Norcross, Georgia, United States. This company, listed on the NASDAQ exchange, is involved in conducting critical research and development in the healthcare industry, focusing on therapeutics that can fight chronic diseases and cancer.
Galectin Therapeutics emphasizes research on galectin proteins, carbohydrate-binding proteins in our bodies, which play a considerable role in controlling inflammation, fibrosis, and even the growth of tumors. It has its research on various types of diseases, including fibrotic diseases and cancer. GALT applies its deep knowledge in complex carbohydrate chemistry and galectin science to develop promising therapies for patients with few treatment options.
The company’s signature product is the belapectin (previously known as GR-MD-02), a compound that targets galectin-3. It is currently the most advanced drug in the company’s pipeline and is being studied for its potential in treating non-alcoholic steatohepatitis (NASH) with cirrhosis, a severe form of non-alcoholic fatty liver disease. This product would bring value to millions of patients who often have to resort to liver transplants.
Galectin Therapeutics is also exploring belapectin’s ability to improve outcomes for cancer patients, given the significant role galectin-3 plays in tumor angiogenesis, the process by which cancerous tumors access blood supply to fuel their growth. It is an exciting avenue in cancer treatment as it seeks to thwart tumor growth by inhibiting its access to blood supply.
Notably, Galectin Therapeutics collaborates with top-tier academic medical research centers, ensuring access to world-class expertise and resources, enhancing its drug development efforts. These collaborations have brought the company considerable recognition and established it as a leading player in researching and developing therapeutics based on galectin proteins.
Galectin Therapeutics Inc. may still be a small cap biotech company, but it is one with significant potential given the innovative work that they are doing. Despite not yet having a product on the market, Galectin's ongoing research into the medical applications of galectin proteins, the cutting-edge nature of their work, and their dedication to addressing severe medical conditions make it an intriguing company in the biotech sector.